We are since April 2019 enrolling patients to a phase I/II clinical trial in chronic myeloid leukemia (CML; PI: Lovisa Wennström), in which we combine tyrosine kinase inhibitors with an NK cell-stimulatory regimen comprising HDC (NOX2 inhibitor) and IL-2. The main focus of the trial is safety, but secondary objectives include studying NK cell activation and therapy-induced effects on the malignant clone. In the long run, we aim to test whether combing NK cell-stimulatory immunotherapy with tyrosine kinase inhibitors may allow patients to quit TKI therapy with maintained treatment-free remission (TFR).

Participating lab members: MD/PhD Lovisa Wennström, PhD student Brwa Hussein, PhD student Hana Komic, Prof Fredrik Bergh Thorén